SCHEMBL6077459

SCHEMBL6077459

Clc1ccc(-c2nsnc2Cl)c(CBr)c1

nearest known ligand 0.32

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CRHR1 P34998 1/20 0.32
CYP3A4 P08684 2/20 0.31
MEN1 O00255 1/20 0.31
SLC22A1 O15245 1/20 0.31
USP2 O75604 1/20 0.31
LMNA P02545 1/20 0.31
HSP90AA1 P07900 1/20 0.31
MAPT P10636 1/20 0.31
HSPD1 P10809 1/20 0.31
HSPA5 P11021 1/20 0.31
IDO1 P14902 1/20 0.31
HPGD P15428 1/20 0.31
ALOX15 P16050 1/20 0.31
ALOX12 P18054 1/20 0.31
CASP1 P29466 1/20 0.31
HTT P42858 1/20 0.31
BLM P54132 1/20 0.31
HSPE1 P61604 1/20 0.31
KMT2A Q03164 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6077418 0.84 CYP2A6 (0.38) CYP3A4MEN1SLC22A1USP2LMNA
SCHEMBL6078239 0.75 NOTUM (0.42) CRHR1CYP3A4MEN1MAPTHPGD
SCHEMBL7817896 0.73 CDC25B (0.32)
SCHEMBL1113833 0.67 FFAR1 (0.45) CYP3A4MEN1HPGDALOX15KMT2A
SCHEMBL6077917 0.67 LMNA (0.42) CYP3A4MEN1SLC22A1USP2LMNA
SCHEMBL30089455 0.66 IDO1 (0.44) CYP3A4MEN1SLC22A1USP2LMNA
SCHEMBL384040 0.66 IDO1 (0.44) CYP3A4MEN1SLC22A1USP2LMNA
SCHEMBL8935466 0.65 KDM4E (0.41) LMNAHSP90AA1MAPTHPGDALOX12
SCHEMBL10983827 0.65 IDO1 (0.45) IDO1SMN1; SMN2
SCHEMBL189771 0.64 TP53 (0.48) CYP3A4MEN1SLC22A1USP2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7144899-B2 Thrombin inhibitors MERCK & CO., INC. (US) 2006-12-05 US disclosed
US-20040073025-A1 Thrombin inhibitors MERCK SHARP & DOHME CORP. 2004-04-15 US disclosed
WO-2002064559-A2 THROMBIN INHIBITORS MERCK & CO., INC. (US) 2002-08-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040073025-A1 Thrombin inhibitors F2, F11, F10 CRHR1 828/4885CYP3A4 2153/4885MEN1 494/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.